| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/06/1997 | WO1997008182A1 Process for the preparation of imidazolyl macrolide immunosuppressants |
| 03/06/1997 | WO1997008180A1 Method to improve the biological and antiviral activity of protease inhibitors |
| 03/06/1997 | WO1997008175A1 Isolation of clavulanic acid from fermentation broth by ultrafiltration |
| 03/06/1997 | WO1997008174A1 Interleukin converting enzyme and apoptosis |
| 03/06/1997 | WO1997008168A1 Pyrrolyl tetrahydroquinoxalin diones, their production and use in the treatment of diseases |
| 03/06/1997 | WO1997008166A1 Piperazino derivatives as neurokinin antagonists |
| 03/06/1997 | WO1997008165A1 New cyclic guanidines, process for preparing the same and medicaments |
| 03/06/1997 | WO1997008159A1 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders |
| 03/06/1997 | WO1997008155A1 Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives |
| 03/06/1997 | WO1997008146A1 Pyridinium derivatives and pharmaceutical compositions containing them |
| 03/06/1997 | WO1997008145A1 Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| 03/06/1997 | WO1997008144A1 Substituted benzylaminopiperidine compounds |
| 03/06/1997 | WO1997008143A1 Inhibitors of tumor necrosis factor alpha |
| 03/06/1997 | WO1997008133A1 Amide compounds and use of the same |
| 03/06/1997 | WO1997008126A1 Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents |
| 03/06/1997 | WO1997007817A1 Multi-subtype fiv vaccines |
| 03/06/1997 | WO1997007815A2 Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| 03/06/1997 | WO1997007814A1 Method and composition for enhanced parenteral nutrition |
| 03/06/1997 | WO1997007807A1 New use of pregnane-diones as analgesic agents |
| 03/06/1997 | WO1997007806A1 Preventive or remedy for kidney diseases |
| 03/06/1997 | WO1997007805A1 Interleukin converting enzyme and apoptosis |
| 03/06/1997 | WO1997007804A1 Combination therapy for advanced cancer comprising temozolomide and cisplatin |
| 03/06/1997 | WO1997007802A1 Methods and compositions for treating fungal infections in mammals |
| 03/06/1997 | WO1997007801A1 New applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl |
| 03/06/1997 | WO1997007800A1 Zwitterionic forms of trovafloxacin |
| 03/06/1997 | WO1997007799A1 Facilitation of ampa receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
| 03/06/1997 | WO1997007798A1 Pharmaceutical compounds |
| 03/06/1997 | WO1997007797A1 Treatment of human prostate disease with beta-lapachone derivatives |
| 03/06/1997 | WO1997007796A1 Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity |
| 03/06/1997 | WO1997007795A2 1-[4-(4'-sulfanilyl)phenyl]urea and derivatives for the treatment of leishmaniasis |
| 03/06/1997 | WO1997007794A1 Composition for local anesthesia |
| 03/06/1997 | WO1997007793A1 Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd) |
| 03/06/1997 | WO1997007792A1 Desbutylhalofantrine compositions and use |
| 03/06/1997 | WO1997007791A1 Use of aminoadamantane compounds as immunoregulators |
| 03/06/1997 | WO1997007790A1 Pharmaceutical compositions for the treatment of infectious diseases |
| 03/06/1997 | WO1997007789A1 Regulation of intracellular glucocorticoid concentrations |
| 03/06/1997 | WO1997007784A2 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES |
| 03/06/1997 | WO1997007772A1 Compositions containing a peptide cell growth promoter |
| 03/06/1997 | WO1997007769A2 Chemical compounds |
| 03/06/1997 | WO1997007757A1 Bismuth-containing compounds in topical dosage forms |
| 03/06/1997 | WO1997007750A1 Administration of ketamine to manage pain and to reduce drug dependency |
| 03/06/1997 | WO1997007685A1 Capsules containing freeze-dried powdered green tea leaves |
| 03/06/1997 | WO1997005285A3 Methods and compositions for identifying morphogen analogs |
| 03/06/1997 | WO1996023479A3 Anti-adhesive active principles |
| 03/06/1997 | DE19532714A1 Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden Combination of 5-lipoxygenase and leukotriene synthesis inhibitors with glucocorticosteroids |
| 03/06/1997 | DE19532668A1 Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung New anticonvulsive action 1-ar (alk) yl-imidazolin-2-ones which contain in the 4-position is disubstituted amine radical, and processes for their preparation |
| 03/06/1997 | DE19532235A1 New antibacterial contg. osteotropic mol. fragments |
| 03/06/1997 | DE19532050A1 Pyrrolyl-tetrahydrochinoxalindione, ihre Herstellung und Verwendung zur Bekämpfung von Krankheiten Pyrrolyl tetrahydrochinoxalindione, their preparation and use for controlling diseases |
| 03/06/1997 | DE19532006A1 Sun protection agents contg. betulinic acid |
| 03/06/1997 | CA2666298A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 03/06/1997 | CA2502764A1 Amide compounds |
| 03/06/1997 | CA2246117A1 Cryptophycins from aberrant biosynthesis |
| 03/06/1997 | CA2230929A1 Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| 03/06/1997 | CA2230856A1 Methods and compositions for treating fungal infections in mammals |
| 03/06/1997 | CA2230654A1 Genetic alterations related to familial alzheimer's disease |
| 03/06/1997 | CA2230648A1 Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd) |
| 03/06/1997 | CA2230578A1 Pyridinium derivatives and pharmaceutical compositions containing them |
| 03/06/1997 | CA2230540A1 Pharmaceutical compounds |
| 03/06/1997 | CA2230532A1 Facilitation of ampa receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
| 03/06/1997 | CA2230487A1 Inhibitors of tumor necrosis factor alpha |
| 03/06/1997 | CA2230448A1 Composition for local anesthesia |
| 03/06/1997 | CA2230359A1 Desbutylhalofantrine compositions and use |
| 03/06/1997 | CA2230209A1 Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| 03/06/1997 | CA2230160A1 Antimicrobial cationic peptides and methods of screening for the same |
| 03/06/1997 | CA2230094A1 Acid resistant calcium carbonate composition containing an aluminum salt and uses therefor |
| 03/06/1997 | CA2230055A1 Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor |
| 03/06/1997 | CA2229903A1 New cyclic guanidines, process for preparing the same and medicaments |
| 03/06/1997 | CA2229718A1 Process for the preparation of imidazolyl macrolide immunosuppressants |
| 03/06/1997 | CA2229141A1 Combination therapy for advanced cancer comprising temozolomide and cisplatin |
| 03/06/1997 | CA2227691A1 Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents |
| 03/06/1997 | CA2227278A1 Method and composition for enhanced parenteral nutrition |
| 03/06/1997 | CA2227040A1 Chemical compounds |
| 03/06/1997 | CA2226963A1 Crystalline zap family proteins |
| 03/06/1997 | CA2203624A1 New applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-¬n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide¦ethyl |
| 03/05/1997 | EP0760482A2 Method for judging eradication of H. pylori based on rates of changes in the pepsinogen I/II ratio |
| 03/05/1997 | EP0760366A1 Prostaglandin derivatives |
| 03/05/1997 | EP0760365A2 Alkenyl-benzoylguanidines |
| 03/05/1997 | EP0760241A1 Use of sulfasalazine and its active metabolite for the manufacture of a medicament for the treatment of venous insufficiency and venous ulcers |
| 03/05/1997 | EP0760240A1 Novel composition stimulating the cerebral activity and based on alcaloids having an eburnamenine nucleus, and preparation methods |
| 03/05/1997 | EP0760239A2 Therapeutic agents for use in cancer therapy |
| 03/05/1997 | EP0760235A1 Hair treating composition |
| 03/05/1997 | EP0760013A1 Treatment of influenza virus infection using antivirals that inhibit acylation/palmitylation of hemagglutinin |
| 03/05/1997 | EP0759992A1 Human papilloma virus inhibition by a hairpin ribozyme |
| 03/05/1997 | EP0759986A1 Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein |
| 03/05/1997 | EP0759984A1 Modulator of tnf/ngf superfamily receptors and soluble oligomeric tnf/ngf superfamily receptors |
| 03/05/1997 | EP0759980A1 Interleukin-6 splice variant |
| 03/05/1997 | EP0759979A1 Antisense inhibition of hepatitis c virus |
| 03/05/1997 | EP0759925A1 Adenosine derivatives |
| 03/05/1997 | EP0759923A1 New agonist compounds |
| 03/05/1997 | EP0759922A1 New antagonist compounds |
| 03/05/1997 | EP0759920A1 Derivatives of quinuclidine n-oxide as muscarinic receptor ligands |
| 03/05/1997 | EP0759919A1 New azolidinediones as antihyperglycemic agents |
| 03/05/1997 | EP0759918A1 Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists |
| 03/05/1997 | EP0759917A1 Novel selective inhibitors of viral or bacterial neuraminidases |
| 03/05/1997 | EP0759912A1 New di-oxadiazole derivatives as antihyperglycemic agents |
| 03/05/1997 | EP0759910A1 Acid amide derivatives and process for the preparation thereof |
| 03/05/1997 | EP0759899A1 Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| 03/05/1997 | EP0759783A1 Anti-inflammatory wound healing compositions and methods for preparing and using same |
| 03/05/1997 | EP0759781A1 Method for treating and preventing atherosclerosis |
| 03/05/1997 | EP0759774A1 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic |